Platelet membrane glycoprotein receptor

Platelet membrane glycoprotein receptors represent a broad and heterogeneous group of surface molecules expressed on platelets, which mediate adhesion, activation, aggregation, and interactions with other blood cells and the vessel wall. Major families include integrins (such as GPIIb/IIIa [αIIbβ3], GPIa/IIa [α2β1]), the GPIb-IX-V complex, immunoglobulin superfamily receptors (e.g., GPVI, PECAM-1), leucine-rich repeat proteins, G protein-coupled receptors (notably ADP and thrombin receptors, such as P2Y₁₂ and PAR1), and others including tetraspanins, tyrosine kinase receptors, P-selectin (CD62P), and CLEC-2[1][2][3]. These receptors mediate the primary steps of hemostasis and thrombosis—involving platelet adhesion to damaged endothelium, activation by soluble agonists (collagen, ADP, thrombin), and platelet-to-platelet aggregation. Because of their central role in arterial thrombosis and hemostasis, several of these receptors are validated therapeutic targets in cardiovascular disease, specifically in acute coronary syndromes and stroke prevention. However, the term itself encompasses numerous distinct molecules with specialized roles, and drug development typically targets individual receptor types such as GPIIb/IIIa or P2Y₁₂[1][3].

Other names

Platelet glycoprotein receptorPlatelet surface receptorPlatelet adhesion receptor

Drugs targeting platelet membrane glycoprotein receptors exert their effects through various mechanisms, including inhibition of platelet aggregation (e.g., GPIIb/IIIa antagonists prevent fibrinogen cross-linking), blockade of ADP-induced platelet activation (P2Y₁₂ antagonists), thrombin receptor antagonism (PAR1 antagonists), and inhibition of cyclooxygenase and thromboxane A2 production (aspirin).